Finally, in MDD, TrkB agonists and TrkB antagonists could act as potential therapeutic drugs for patients with lower BDNF levels in the hippocampus and PFC, and those with higher levels of BDNF in the NAc. The gene discussed is NTRK2; the disease is major depressive disorder.